1. Introduction {#sec1}
===============

Glucagon-like peptide 1 (GLP-1) is released from enteroendocrine L-cells after food intake and stimulates insulin release, reduces appetite and slows down gastric emptying [@bib1]. GLP-1 has a short half-life (∼2 min) and is rapidly degraded by dipeptidyl peptidase 4 (DPP4), and currently available GLP-1-based drugs are GLP-1 receptor agonists and DPP4 inhibitors [@bib2]. However, although these drugs offer advantages over traditional anti-diabetic drugs as they promote weight loss and are associated with a lower risk of hypoglycemia [@bib3], GLP-1 receptor agonists are only available as injections and the safety profile of both drug classes for long-term treatment is under debate [@bib4].

There is an increasing interest in the genetic modification of food-grade bacteria to express potentially therapeutic eukaryotic peptides. *Lactococcus lactis* is a homofermentative Gram-positive bacterium used as a starter culture in a wide variety of fermented food products. Its small genome size, the availability of tightly regulated promoter systems, mild proteolytic activity and generally-regarded-as-safe status make it an ideal host for the production, secretion and delivery of peptides directly to the intestine [@bib5]. Recombinant interleukin 10-producing *L. lactis* has been shown to protect against colitis in mouse models [@bib6] and is now being tested in a phase 2a clinical trial in patients with Crohn\'s disease [@bib7], indicating the potential of recombinant bacterial strains in the treatment of human disease.

Here, we developed a genetically modified *L. lactis* strain to produce murine GLP-1 and investigated its potential to improve glucose tolerance in wild-type (WT) mice either on chow or high-fat diet (HFD). GLP-1 receptor knock out (GLP1R-KO) mice on chow diet were used as a negative control to assess the specificity of LL-GLP1 in improvement of glucose tolerance.

2. Methods {#sec2}
==========

2.1. Construction of recombinant GLP-1-producing *L. lactis* {#sec2.1}
------------------------------------------------------------

A 206-bp synthetic gene construct encoding the murine GLP-1 peptide (1--37) N-terminally fused to the lactococcal Usp45 signal peptide was created *in silico* and its codon usage was optimised for lactococcal expression. The resulting gene cassette was obtained through gene synthesis and subsequently cloned into the *E. coli* plasmid pEX-A (Eurofins, Germany). The cassette contains NcoI and BamHI restriction sites at its 5′ and 3′ ends, respectively, allowing for the translational fusion of the gene to the *nisA* start codon in the lactococcal expression vector pUK200 [@bib8]. The gene was excised from pEX-A using NcoI and BamHI and ligated into pUK200, which had been restricted in the same way, resulting in plasmid pUK200_GLP1. The empty vector and the nisin-inducible GLP-1 expression vector ([Figure 1](#fig1){ref-type="fig"}A) were then transformed into the nisin-producing strain *L. lactis* FI5876 [@bib9] to generate strains FI10936 (LL-UK200) and FI10937 (LL-GLP1), respectively.

2.2. Culture conditions {#sec2.2}
-----------------------

Both *L. lactis* strains were grown overnight at 30 °C for 16 h in M17 media (pH 7.0) supplemented with glucose (2% wt/vol). Thereafter, the cultures were pelleted and subsequently resuspended in fresh M17 media (pH 8.5) supplemented with glucose (2% wt/vol). Growth was observed for an additional ∼3 h until the pH reached 7.0. Active GLP-1 in the culture supernatant was measured at this time point using the Mesoscale discovery kit.

2.3. Mice {#sec2.3}
---------

All procedures in mice were approved by the Ethics Committee on Animal Care and Use in Gothenburg, Sweden. Male C57/bl6 and GLP1R-KO mice aged 10--12 weeks of age were used mice were either bred in-house (for chow study) or purchased from Taconic, Denmark (for HFD study).

### 2.3.1. Glucose-stimulated insulin release from isolated islets {#sec2.3.1}

Islets were isolated from WT and GLP1R-KO mice using collagenase perfusion as described before [@bib10]. Five islets per group were incubated with 16 mmol/l glucose-Krebs ringer buffer (G-KRB), 2 μmol/l exendin-4 prepared in G-KRB (positive control) or cell-free supernatants from LL-UK200 or LL-GLP1 cultures diluted 1:4 in G-KRB at 37 °C for 60 min. After incubation, islets were sedimented and insulin was measured in the supernatants using the insulin ELISA kit (Crystal Chem). All stimulations were performed in duplicate and repeated three times independently.

### 2.3.2. *In vivo* study {#sec2.3.2}

We performed two *in vivo* studies to investigate the effect of LL-GLP1 on glucose tolerance. In the first study, WT or GLP1R-KO mice were randomised on an autoclaved low-fat polysaccharide-rich chow diet (LabDiet, St Louis, MO, USA) *ad libitum* and they received 200 μl oral daily gavages of fresh bacterial culture containing 1 × 10^10^ colony forming units (cfu) of either LL-UK200 or LL-GLP1 cultures for 9 days. In the second study, WT mice were randomised to receive 200 μl oral daily gavages of fresh LL-UK200 or LL-GLP1 cultures for 3 weeks on chow followed by 3 weeks onto a high-fat, high-sugar western diet with 40% of calories from fat (Adjusted Fat Diet TD.96132, Harlan Teklad, Indianapolis, IN, USA). Body weight and body fat (measured by whole body magnetic resonance imaging) were measured at the indicated time points.

Intraperitoneal glucose tolerance tests (IPGTT) and insulin tolerance tests (ITT) were performed at the end of each study. For IPGTT, mice were fasted for 4 h and injected intraperitoneally with a 20% glucose solution prepared in PBS (1 mg/g body weight). Blood was drawn from the tail vein before and after the glucose injection (at −30, 0, 15, 30, 60, 90 and 120 min) and blood glucose was measured using a Bayer glucometer. Additional blood was collected for insulin measurement at 0, 15 and 30 min. Insulin was measured by ELISA (CrytalChem). For ITT, mice were fasted for 4 h and injected intraperitoneally with insulin (0.75 U/kg body weight). Blood was drawn from the tail vein at 0, 15, 30, 60, 90 and 120 min for blood glucose measurements.

Blood from the vena porta and the vena cava was collected at the end of all experiments; 5 μl DPP4 inhibitor and 2 μl aprotinin (Millipore) were added to EDTA tubes and syringes before blood collection to prevent the degradation of GLP-1. Active GLP-1 was measured using the Mesoscale discovery kit. Liver tissue and intestinal contents from ileum, caecum and colon were collected and snap frozen.

2.4. Quantitative PCR for *L. lactis* {#sec2.4}
-------------------------------------

Bacterial DNA was extracted from intestinal content of mice using the Machery Nagel NucleoSpin^®^ Soil kit. The DNA was diluted to a concentration of 1 ng/μl and the total number of recombinant *L. lactis* cells was determined in a SYBR green-based qPCR using forward primer 5′-CCTTCTACCCATTATTACAGCAGG-3′ and reverse primer 5′-ACCACGACCTTTAACAAGCC-3′. The colonization level of LL-GLP1 was determined using forward primer 5′-AGCGAAGATGTTGTCTGTTAG-3′ and reverse primer 5′-GGCACTCGGCACTTAATG-3′. Total genomic DNA extracted from LL-GLP1 was used as standard.

2.5. RNA extraction and quantitative PCR {#sec2.5}
----------------------------------------

Mouse tissues were homogenised in RLT buffer supplemented with 2-mercaptoethanol using 5 mm steel beads and TissueLyser (Qiagen, Hilden, Germany). RNA was extracted using the RNeasy Kit with on-column DNase I treatment (Qiagen). RNA quantity and quality were examined with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies). cDNA was synthesised using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). qRT-PCR reactions were set up in a 10 μl volume containing 1× SYBR Green Master Mix buffer (Thermo Scientific) and 900 nM gene-specific primers (or 300 nM L32 primers). Reactions were run on a CFX96 Real-Time System (Bio-Rad). Gene expression data were normalized to the ribosomal protein L32 using the ΔΔCT method. The primer sequences for phosphoenolpyruvate carboxykinase (*Pepck*) and glucose 6 phosphatase, catalytic subunit (*G6pc*) are forward 5′-GGCCACAGCTGCTGCAG-3′, reverse 5′- GGTCGCATGGCAAAGGG-3′, and forward 5′-CTGTGAGACCGGACCAGGA-3′, reverse 5′- GACCATAACATAGTATACACCTGCTGC-3′, respectively.

2.6. Statistical analysis {#sec2.6}
-------------------------

Data are shown as mean ± SEM. Unpaired Student\'s t test (for 2 groups) was performed to determine the significance between groups using GraphPad Prism software. Significance was established at *p* \< 0.05.

3. Results {#sec3}
==========

3.1. Effect of LL-GLP1 on *ex vivo* insulin secretion {#sec3.1}
-----------------------------------------------------

No GLP-1 was detectable in the culture supernatant of LL-UK200 but we measured 130 pg/ml of active GLP-1 in the culture supernatant of LL-GLP1. No difference in growth rates was observed between the two strains (data not shown). To determine the biological potential of the GLP-1 containing supernatant, we incubated primary islets isolated from WT or GLP1R-KO mice with LL-UK200 or LL-GLP1 culture supernatants (or exendin-4 as a positive control) under conditions of high glucose concentrations. Insulin release from primary islets from WT mice was significantly higher following incubation with LL-GLP1 compared with LL-UK200 culture supernatant ([Figure 1](#fig1){ref-type="fig"}B). This difference was not observed in islets from GLP1R-KO mice ([Figure 1](#fig1){ref-type="fig"}B), indicating that the biological response to the recombinant peptide was dependent on the GLP-1 receptor.

3.2. Effect of LL-GLP1 on glucose tolerance in chow-fed mice {#sec3.2}
------------------------------------------------------------

To investigate the *in vivo* functionality of these strains, we first administered LL-UK200 and LL-GLP1 to WT mice on chow diet once daily for 9 days. By performing qPCR, we showed that the density of total recombinant *L. lactis* and LL-GLP1 was highest in the caecum followed by the colon and both strains were undetectable in the ileum (data not shown). The total recombinant *L. lactis* count in the caecal contents was similar in LL-UK200 and LL-GLP1 administered mice ([Figure 2](#fig2){ref-type="fig"}A) whereas LL-GLP1 was only present in the caecum of mice that received LL-GLP1 ([Figure 2](#fig2){ref-type="fig"}B). Active GLP-1 levels were significantly higher in the vena porta and showed a tendency to increase in the vena cava of mice treated with LL-GLP1 compared with LL-UK200 ([Figure 2](#fig2){ref-type="fig"}C). There was no significant effect of LL-GLP1 versus LL-UK200 administration on body weight ([Figure 2](#fig2){ref-type="fig"}D) or fat percentage ([Figure 2](#fig2){ref-type="fig"}E) over the study period.

Glucose tolerance (determined by an IPGTT) was improved in WT mice treated with LL-GLP1 compared with mice treated with the LL-UK200 control strain at the end of the study period ([Figure 2](#fig2){ref-type="fig"}F). However, there was no significant difference in insulin levels ([Figure 2](#fig2){ref-type="fig"}G) nor insulin tolerance ([Figure 2](#fig2){ref-type="fig"}H) between the two groups of mice. Hepatic expression of *G6pc* was reduced in LL-GLP1 supplemented mice ([Figure 2](#fig2){ref-type="fig"}I).

To determine if the improved glucose tolerance in response to LL-GLP1 administration was dependent on the GLP-1 receptor, we administered LL-UK200 and LL-GLP1 to GLP1R-KO mice on chow diet once daily for 9 days. The density of LL-GLP1 in caecal contents of GLP1R-KO mice ([Supplementary Figure 1A](#appsec2){ref-type="sec"}) was similar to that observed in WT mice ([Figure 2](#fig2){ref-type="fig"}B). Active GLP-1 levels were also significantly higher in the vena porta of GLP1R-KO mice treated with LL-GLP1 compared with LL-UK200 ([Supplementary Figure 1B](#appsec2){ref-type="sec"}). However, no changes in glucose tolerance were observed in GLP1R-KO mice administered with either LL-GLP1 or LL-UK200 ([Supplementary Figure 1C](#appsec2){ref-type="sec"}), indicating a requirement of GLP-1 receptor for the biological response to LL-GLP1.

3.3. Effect of LL-GLP1 on glucose tolerance in HFD-fed mice {#sec3.3}
-----------------------------------------------------------

To investigate the functionality of LL-GLP1 in a model of impaired glucose tolerance, we tested the effect of LL-UK200 and LL-GLP1 in mice challenged with a HFD. LL-UK200 and LL-GLP1 were administered once daily for 3 weeks to mice on a chow diet and then for a further 3 weeks to the same mice on a HFD. Similar to the mice that received the strains for 9 days on a chow diet, the total recombinant *L. lactis* count in the caecal contents was similar in LL-UK200 and LL-GLP1 administered mice ([Figure 3](#fig3){ref-type="fig"}A), whereas LL-GLP1 was only present in the caecum of mice that received LL-GLP1 ([Figure 3](#fig3){ref-type="fig"}B). Active GLP-1 levels showed a tendency to increase in the vena porta of mice treated with LL-GLP1 compared with LL-UK200 ([Figure 3](#fig3){ref-type="fig"}C). There was no significant effect of LL-GLP1 versus LL-UK200 administration on body weight ([Figure 3](#fig3){ref-type="fig"}D) or fat percentage ([Figure 2](#fig2){ref-type="fig"}E) over the 6-week study period.

As expected, mice treated with the LL-UK200 control strain and fed a HFD for the final 3 weeks of the study had impaired glucose tolerance together with high fasting glucose and insulin levels ([Figure 3](#fig3){ref-type="fig"}F,G) compared with mice on chow ([Figure 2](#fig2){ref-type="fig"}F,G). Administration of LL-GLP1 promoted a significant improvement in glucose tolerance together with increased fasting insulin levels, and increased insulin levels 15 and 30 min after the glucose injection for the IPGTT ([Figure 3](#fig3){ref-type="fig"}F,G). Insulin tolerance did not differ between the LL-GLP1 and LL-UK200 groups ([Figure 3](#fig3){ref-type="fig"}H). Expression of *Pepck* was slightly increased whereas *G6pc* was reduced in the liver of LL-GLP1 supplemented mice on a HFD ([Figure 3](#fig3){ref-type="fig"}I).

4. Discussion {#sec4}
=============

In the present study, we generated a recombinant *L. lactis* strain that produced GLP-1 and demonstrated its biological efficacy in stimulating insulin secretion from primary islets of WT but not GLP1R-KO mice. In mice on a chow diet, glucose tolerance was improved following administration of LL-GLP1 versus the control LL-UK200 in WT but not in GLP1R-KO mice, indicating a requirement for the GLP-1 receptor. Similarly, supplementation with LL-GLP1 promoted a pronounced improvement in glucose tolerance together with increased insulin levels in mice fed HFD. Supplementation with LL-GLP1 versus LL-UK200 did not affect insulin tolerance but resulted in reduced expression of *G6pc* in both chow and HFD-fed mice.

A previous study has shown that *L. lactis* genetically modified to produce GLP-1 could stimulate insulin release from a pancreatic beta cell line HIT-T15 [@bib11]. However, an advantage of our study is that we used islets from WT and GLP1R-KO mice, and could thus show that the effect of LL-GLP1 on insulin secretion was specifically mediated through the GLP-1 receptor. Furthermore, we showed that mice on a chow diet treated with LL-GLP1 versus LL-UK200 had higher vena porta levels of GLP-1. Although we cannot differentiate between endogenous and recombinant *L. lactis*-derived GLP-1, this observation suggests that GLP-1 was constitutively synthesised by LL-GLP1 and continuously diffused into the portal circulation. Our results are in accordance with a previous report that showed increased circulating levels of biologically active interleukin 12 after administration of genetically engineered *L. lactis* [@bib12].

Although mice on a chow diet exhibited improved glucose tolerance in an IPGTT following supplementation with LL-GLP1 versus LL-UK200, no difference in insulin levels was observed. This result was surprising as many studies have reported that GLP-1 has a post-prandial insulinotropic effect under physiological conditions [@bib13]. However, in light of its short half-life and non-proximity of L-cells with the pancreas, it has been proposed that GLP-1 is also sensed by the hepato-portal GLP-1 receptor that stimulates insulin-independent glucose clearance [@bib14]. The presence of the GLP-1 receptor in extra pancreatic tissues such as the liver is still debated [@bib15], but GLP-1 therapy has been reported to reduce expression of genes involved in hepatic gluconeogenesis, thereby reducing hepatic glucose production [@bib16]. In agreement with this, we observed decreased expression of *G6pc* in mice supplemented with LL-GLP1, which may contribute to the improved glucose tolerance in the absence of altered insulin levels in mice on a chow diet.

We also investigated the effect of LL-GLP1 and LL-UK200 supplementation in HFD-fed mice, which is a robust model for impaired glucose tolerance [@bib17]. Using this model, we observed a pronounced improvement of glucose tolerance together with increased insulin levels in mice supplemented with LL-GLP1 versus LL-UK200. Similar improvement in glucose tolerance (mixed meal over 8 h) coupled with high fasting and 8 h insulin levels was observed in patients with type 2 diabetes when they were assigned continuous subcutaneous infusion of GLP-1 for 6 weeks [@bib18]. HFD is known to reduce the incretin effect, and earlier studies in mice have shown that HFD reduces the colonic expression of proglucagon, the gene that expresses GLP-1, and circulating GLP-1 levels [@bib10], [@bib19]. Our results suggest that the constitutive synthesis of GLP-1 by the modified *L. lactis* strain can compensate for the reduction in incretin response induced by HFD. Additionally, reduced expression of *G6pc* may also account for reduced glucose output from liver thus contributing to an improved glucose metabolism.

Taken together, we demonstrated the efficacy of a *L. lactis* strain genetically modified to produce GLP-1 in stimulating insulin secretion in isolated mouse islets and improving glucose tolerance in mice on either chow or a HFD. In summary, these findings provide evidence that recombinant *L. lactis* strains may have potential clinical applications, although further research is clearly required.
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The following is the supplementary data related to this article:Supplementary Figure 1**Recombinant LL-GLP1 requires GLP-1 receptor to exert its beneficial effects**. (**A**) Copies of LL-GLP1 in caecal content, (**B**) GLP-1 levels in vena porta and vena cava, and (**C**) glucose levels before and during an intraperitoneal glucose tolerance test in chow-fed GLP-1 receptor knockout mice (GLP1R-KO, n = 6--9) supplemented with LL-UK200 or LL-GLP1 for 9 days. \*p \< 0.05, LL-GLP1 versus LL-UK200.

We thank Rosie Perkins for editing the manuscript and are grateful to Carina Arvidsson, Sara Nordin-Larsson, Ulrica Enqvist, Caroline Wennberg and Zakarias Gulic for excellent animal husbandry. This study was supported by the Swedish Research Council Formas, Torsten Söderberg\'s Foundations, Ingabritt and Arne Lundberg\'s Foundation, Swedish Foundation for Strategic Research, Knut and Alice Wallenberg Foundation, and the regional agreement on medical training and clinical research (ALF) between Region Västra Götaland and Sahlgrenska University Hospital. FB is a recipient of ERC Consolidator Grant (European Research Council, Consolidator grant 615362 -- METABASE). AN was supported by Biotechnology and Biological Sciences Research Council (BBSRC) strategic grant and both FB and AN received funding from EU FP7 TORNADO programme.

Supplementary data related to this article can be found at [http://dx.doi.org/10.1016/j.molmet.2016.06.006](10.1016/j.molmet.2016.06.006){#intref0010}.

![***In vitro* insulin release by recombinant *L. lactis*-derived GLP-1**. (**A**) GLP-1 vector expressing murine GLP-1. (**B**) Insulin release from pancreatic islets of wild-type (WT, n = 3) and GLP-1 receptor knock out (GLP1R-KO, n = 3) mice treated with buffer alone (blank), exendin-4 (Ex4, positive control) or culture supernatant from recombinant LL-GLP1 or vector control LL-UK200. All stimulations were performed in duplicate. Data are mean ± SEM. \*\*\*p \< 0.001.](gr1){#fig1}

![**Effect of recombinant LL-GLP-1 in chow-fed mice**. Copies of (**A**) total recombinant *L. lactis* and (**B**) LL-GLP1 in caecal contents of chow-fed mice (n = 12) supplemented with LL-GLP1 or the vector control LL-UK200 for 9 days. (**C**) GLP-1 levels in vena porta and vena cava plasma of chow-fed mice (n = 7) supplemented with LL-GLP1or LL-UK200 for 9 days. (**D**) Body weight curves and (**E**) fat percentage before and after 9 days of treatment in chow-fed mice (n = 5) supplemented with LL-UK200 or LL-GLP1. (**F**) Glucose and (**G**) insulin levels before and during an intraperitoneal glucose tolerance test and (**H**) glucose excursions during an insulin tolerance test in chow-fed mice (n = 11) supplemented with LL-UK200 or LL-GLP1 for 9 days. (**I**) Relative expression of *Pepck* and *G6pc* in the liver of chow-fed mice (n = 12) supplemented with LL-UK200 or LL-GLP1 for 9 days. Data are mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, LL-GLP1 versus LL-UK200.](gr2){#fig2}

![**Effect of recombinant LL-GLP1 in HFD-fed mice**. Copies of (**A**) total recombinant *L. lactis* and (**B**) LL-GLP1 in caecal contents of mice (n = 7--8) supplemented with LL-UK200 or LL-GLP1for 3 weeks on chow followed by 3 weeks on a HFD. (**C**) GLP-1 levels in vena porta and vena cava plasma at the end of the study, (**D**) body weight curves for the final 3 weeks of the study and (**E**) fat percentage at the indicated times in mice (n = 7--8) supplemented with LL-UK200 or LL-GLP1 for 3 weeks on chow followed by 3 weeks on a HFD. (**F**) Glucose and (**G**) insulin levels before and during an intraperitoneal glucose tolerance test, (**H**) glucose excursions during an insulin tolerance test, and (**I**) relative expression of *Pepck* and *G6pc* in the liver of mice (n = 7--8) supplemented with LL-UK200 or LL-GLP1for 3 weeks on chow followed by 3 weeks on a HFD. Data are mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, LL-GLP1 versus LL-UK200.](gr3){#fig3}
